Shawn Maddaford, PhD

President and CSO

  • 25 Years of drug discovery and development experience
  • Cofounder of three chemistry-based R&D companies  for CNS and other disorders:  Cofounder and V.P. Discovery Chemistry at NeurAxon; raised more than $60M in capital. MCR Research and Talon Pharmaceuticals.
  • Senior Scientist; Allelix/NPS – Therapeutics for migraine and schizophrenia.  Co-discover of novel GLYT1 receptor antagonists that entered clinical trials.
  • Multiple drugs from discovery through Phase II clinical in neurological disorders (pain, migraine, schizophrenia).
  • Led medicinal chemistry, patent strategy and filing and CMC efforts
  • >100 issued patents and applications, >40 publications and abstracts.

Philippe Huot, MD, PhD

Associate Professor, McGill University

  • Associate Professor and Movement Disorder Neurologist at McGill University, Montreal Neurological Institute.
  • Translational research into the discovery of therapeutics to treat motor and non-motor complications of L-DOPA therapy in Parkinson’s.
  • Université Laval (MD, Neurology), University of Toronto (PhD).
  • Over 100 peer-reviewed publication.

Malik Slassi, PhD

Senior Scientific Advisor

  • Co-founder, Senior V.P. Innovation at Mindset Pharma (acquired by Otsuka Pharmaceutical Co) . Founder, President and CSO of Fluorinov Pharma Inc. acquired by Trillium.
  • >30 years of experience with 25 late stage preclinical and clinical small molecule drug candidates in oncology, neurology and gastro-intestinal disorders.  
  • VP of Medicinal Chemistry at Trillium Therapeutics, NPS /Allelix Pharmaceuticals, Cascade Therapeutics, Boehringer Ingelheim Research Inc., and Rhône Poulenc
  • 130 issued patents and applications, 65 publications